Table 1 Amivantamab Side Effect Profile (based on Park et al., JCO 2021)
From: The development of amivantamab for the treatment of non-small cell lung cancer
EGFR-Specific AEs | Rate | MET-Specific AEs | Rate |
|---|---|---|---|
Rash | 86% | Hypoalbuminemia | 27% |
Paronychia | 45% | Peripheral edema | 18% |
Stomatitis | 21% | Â | Â |
Pruritis | 17% | Â | Â |
Diarrhea | 12% | Â | Â |
| Â | Both | ||
Infusion-Related Reactions | 66% | ||